Irinotecan Liposome Combined With Oxaliplatin and Tegafur as Adjuvant Therapy for Pancreatic Cancer

This trial is testing a combination of three chemotherapy drugs — liposomal irinotecan, oxaliplatin, and tegafur — as follow-up (adjuvant) treatment after pancreatic cancer surgery. The goal is to see whether this combination extends survival compared to standard post-surgery treatment. **You may be eligible if...** - You are in good physical condition (ECOG 0–1) - You have had surgery to remove ductal pancreatic adenocarcinoma, with all visible cancer removed (R0 or R1 resection) - Your life expectancy is at least 6 months - You are willing and able to sign an informed consent form **You may NOT be eligible if...** - You cannot eat by mouth or have delayed stomach emptying after surgery - You have significant diarrhea (more than 4 times per day) - Your cancer has already spread to distant organs (metastatic) - You have poor organ function (liver, kidneys, or bone marrow) - You have had previous treatment for pancreatic cancer before surgery Talk to your doctor to see if this trial is right for you.